Glucagon-like peptide-1 derived cardioprotection does not utilize a KATP-channel dependent pathway: mechanistic insights from human supply and demand ischemia studies.

What Was Tested

This randomized controlled trial looks at Glucagon.

Glucagon-like peptide-1 (7-36) amide (GLP-1) protects against stunning and cumulative left ventricular dysfunction in humans.

The mechanism remains uncertain but GLP-1 may act by opening mitochondrial K-ATP channels in a similar fashion to ischemic conditioning.

Who Took Part

The age groups tagged for this paper are teenagers, young adults, adults, middle-aged adults, older adults and people over 80, both men and women.

Thirty-two non-diabetic patients awaiting stenting of the left anterior descending artery (LAD) were allocated into 4 groups (control, glibenclamide, GLP-1, and GLP-1 + glibenclamide).

In a non-invasive study, 10 non-diabetic patients were randomized to receive two dobutamine stress echocardiograms (DSE) during GLP-1 infusion with or without oral glibenclamide pretreatment.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Glucagon study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Glibenclamide was given orally prior to the procedure.

A left ventricular conductance catheter recorded pressure-volume loops during a 1-min low-pressure balloon occlusion (BO1) of the LAD.

GLP-1 or saline was then infused for 30-min followed by a further 1-min balloon occlusion (BO2).

What Was Measured

Topics PubMed links to this paper include Coronary Artery Disease, Coronary Vessels, Echocardiography, Stress, Glucagon-Like Peptide 1, Glyburide, Myocardial Ischemia and Potassium Channels.

Author keywords: Cardioprotection, Glucagon-like peptide-1, Ischemia–reperfusion injury and KATP.

What This Means in Plain Language

The paper is a randomized study of Glucagon.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2016 (Cardiovascular diabetology), a journal based in England.

More context: the Glucagon compound page, all human trials.